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The two objectives of this study were to determine the range of recom- 
mended follow-up strategies for patients with lung cancer treated with 
curative intent and to estimate the cost of such follow-up. Ten articles 
delineating eight specific follow-up strategies were identified from a Med- 
line search of the literature for 1980 through 1995. An economic analysis 
was done of the costs associated with the identified strategies, Charge data 
obtained from the Part B Medicare Annual Data file and the Hospital 
Outpatient Bill file were used as a proxy for cost. Follow-up intensity varied 
widely across strategies for 5 years of posttreatment follow-up. Medicare- 
allowed charges for 5-year follow-up ranged from a low of $946 to a high of 
$5645. When Medicare-allowed charges were converted to a proxy for actual 
charges by a conversion ratio of 1.62, the range was $1533 to $9145, a 
fivefold difference in charges. There was no indication that more intensive, 
higher-cost strategies increased survival or quality of life. The published 
literature, including textbooks, holds few answers in this area. (J Thorac 
Cardiovasc Surg 1996;112:356-63) 
F ollow-up of patients with cancer has been a frequently overlooked research topic with no 
widely accepted practice guidelines, weak attempts 
at measuring costs, and the potential for unre- 
strained costs. 1Among the estimated 180,000 new 
cases of primary lung cancer projected to be diag- 
nosed in the United States this year, approximately 
35,000 patients are treated with curative intent and 
enter follow-up programs. 2' 3 Approximately 30%, 
65%, and 80%, respectively, of patients undergoing 
resection because of TNM stage I, II, and III cancers 
will have recurrence within 5 years. 4-6 Few of these 
recurrences are curatively treated. Second primary 
cancers will develop in approximately 2% to 3% of the 
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same 35,000 patients each year (many of which are 
new lung cancers), a risk that is relatively constant 
during at least the first 5 years after t eatment. 5' 7. 8 
Only 40% to 70% of second primary lung cancers 
are treated with curative intent. 9' 10 
Follow-up regimens generally consist of some 
combination of office visits, chest roentgenography, 
complete blood cell counts (CBCs), liver function 
tests, sputum cytologic tests, bronchoscopy, com- 
puted tomography (CT) of the chest, CT of the 
head, bone scans, magnetic resonance imaging 
(MRI) of the chest, and MRI of the head. In the 
design of surveillance strategies, combining modal- 
ities has been recommended sothat recurrences and 
second primary tumors are detected earlier with the 
goal of facilitating potentially curative treatment or 
providing appropriate palliation. No single modality 
is simultaneously sensitive, specific, safe, inexpen- 
sive, and convenient. Each is valuable for detecting 
specific types of lesions. 
Chest roentgenography has remained the primary 
diagnostic follow-up modality for patients with lung 
cancer, despite the Cooperative Early Lung Cancer 
Detection Program findings, which failed to demon- 
strate a survival advantage for systematic primary 
lung cancer screening. 11"13 The value of any test in 
detecting recurrence is unknown. Although chest 
CT and MRI frequently provide more precise ana- 
tomic depiction than chest roentgenography, both 
are also often nonspecific. 14
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Chest CT, though only moderately sensitive and 
specific, is considered the most accurate and cost- 
effective modality for the evaluation of potential 
neoplasms identified on chest roentgenography and 
is also usefu~ for staging. 15' 16 MRI of the chest, an 
alternative modality previously touted as being more 
accurate than CT, has not been proven superior to 
CT in staging primary bronchogenic cancer, and its 
utility in diagnosing recurrent cancer or new primary 
lung cancer is not known. 17-19 Because of its high 
cost and limited accessibility, MRI is not used as 
frequently as CT. 2° For the detection of brain 
metastases, MRI and CT are similarly sensitive and 
specific, but the yield is low unless symptoms and 
signs of central nervous system metastases are 
present)l. 22 
Positron emission tomography appears promising 
for the differentiation of benign from malignant 
solitary lung nodules, with a sensitivity of 97% and a 
specificity of 82%, 23 and has been useful in staging 
disease in individual patients. Its overall role in 
posttreatment surveillance is currently unknown. 
As a follow-up test to detect recurrence after 
operation, whole-body gallium scan has generated 
some interest, with a sensitivity of 77% and a 
specificity of 59% in some series. 24 Others have not 
been able to duplicate these results, however, and it 
is not in common use. 2° 
According to the Cooperative Early Lung Cancer 
Detection Program study conducted at the Mayo 
Clinic, Johns Hopkins University, and the Memorial 
Sloan-Kettering Cancer Center, conventional spu- 
tum cytologic testing can detect only a small per- 
centage of lung cancers and provides no additional 
benefit over regular chest roentgenography. 11-13 
Preliminary results from an ongoing study suggest 
that immunostaining of these specimens may lead to 
the earlier detection of second primary tumors, but 
at much higher cost. 25 With the use of archived 
specimens from the National Cancer Institute- 
Johns Hopkins University study, 11 Tockman and 
associates 26demonstrated that two monoclonal an- 
tibodies against small cell and non-small-cell ung 
cancer 27' 28 could predict the later development of 
lung cancer up to 2 years earlier than conventional 
cytologic testing with a sensitivity of 91% and a 
specificity of 88%. This approach must be consid- 
ered experimental t present. 
Repeated examinations with a flexible broncho- 
scope are not recommended for screening most 
patients, athough individual patients undoubtedly 
benefit. 29 In addition, regular bronchoscopic studies 
are unpleasant and costly to the patient. Generally, 
bronchoscopic studies are reserved for the evalua- 
tion of disease in patients with symptoms, abnormal 
physical findings, or lesions on imaging tests. 3°' 31 
When brush biopsy, imprint cytologic testing, and 
forceps biopsy are used in conjunction with bron- 
choscopy, a sensitivity of 97.3% and a specificity of 
100% can be achieved. 32 
Various surveillance programs have been advo- 
cated after curative treatment of many solid tumors 
(that is, breast and colon), but little has been written 
about postoperative surveillance for lung cancer. 
Naunheim and associates 2° reviewed several widely 
respected textbooks of thoracic surgery 33-36 and 
found that only one textbook lists the topic in the 
index, 36 athough it is briefly covered in Roth and 
colleagues. 35 Another more recent textbook also 
addresses the issue. 37 Unfortunately, very little of 
what has been advocated is supported by objective 
data. It appears likely that physicians imply adopt 
the surveillance regimen specific to their training 
program. Because there are few analyses of whether 
intensity of follow-up actually benefits patients, this 
practice is difficult to justify. 
The majority of recent reports recommend from 
10 to 14 office visits and one or fewer chest CTs 
during the initial 5 years of follow-up, s' 2o, 37-43 How- 
ever, for all other follow-up methods, the range of 
tests used and the frequency of testing vary widely. 
Two prospective studies have been conducted to 
date, but neither used a randomized controlled trial 
design to compare outcomes of varying intensities of 
follow-up. There is currently no persuasive vidence 
that intensive follow-up detects recurrences and 
second primary tumors earlier, promotes earlier 
treatment of such lesions, lengthens urvival, or 
improves quality of life. 8' 39 
With disagreement over the appropriate fre- 
quency of follow-up and no solid data on which to 
base surveillance strategies, it is not surprising that 
few attempts have been made to ascertain the costs 
associated with follow-up of patients with lung can- 
cer. Walsh and associates 8 retrospectively measured 
institution-specific charges for follow-up of patients 
with lung cancer at a single large cancer center for 
three subgroups of patients: those without recur- 
rence during follow-up (n = 223), those with pallia- 
tively treated recurrence (n = 95), and those with 
curatively treated recurrence (n = 40). Charges 
included follow-up visit and diagnostic test charges, 
as well as treatment charges. It is unclear whether 
drug costs were also factored into the analysis. 
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Table I. Total visits, tests, and charges for initial 5 years of follow-up after treatment across various strategies 
Total visits, tests, charges 
Source Ofice v&it CBC Chem 3 LFT CXR Chest CT Head CT Bone scan 
Williams, 198143; Pairolero, 19845 12 12 0 0 12 0 0 0 
Beattie, 19824I 
Original? 10 0 0 4 10 0 0 0 
Revised (personal communication, 1995) 17 0 0 0 17 0 0 0 
Ginsberg, 198942; Martini, 199537 14 0 0 0 14 0 0 0 
In patients with squamous cell carcinoma 14 0 0 0 14 0 0 0 
Fischer, 19963s 22 11 11 0 22 0 0 0 
Toporoff, 199540 14 0 0 14 14 0 0 0 
Virgo, 1995395 
Intensive 14 5 0 0 7 2 0 1 
Nonintensive 7 2 0 0 3 0 0 1 
Walsh (in press) a 6 0 0 0 6 0 0 0 
Naunheim (in press) 2° 11 4 0 4 11 1 0 0 
Chem 3, Defined here as alkaline phosphatase, partate aminotransferase, and bilirubin; LFT, 
carcinoembryonic antigen. 
*Medicare charges times 1.62 conversion ratio. 
tOnly 2 years of follow-up listed under original strategy. 
SActual patient follow-up during disease-free interval. No set follow-up protocol was imposed. 
liver function test; CXR, chest roentgenography; CEA, 
Average monthly charges were $365 for patients 
without recurrence, $859 for patients palliatively 
treated for recurrence, and $1256 for patients cura- 
tively treated for recurrence. No attempt was made 
to apply nationwide charges to the surveillance data, 
although generalizability might have been improved 
had this been done. 
In a similar, though much smaller study, Virgo 
and colleagues (unpublished manuscript) measured 
the charges for follow-up of patients with lung 
cancer at a single Veterans Affairs (VA) medical 
center during an l 1-year period for two groups of 
patients: those followed up intensively (n = 120) 
and those followed up nonintensively (n = 62). 
Because the VA does not calculate charges for 
billing purposes, 1992 nationwide average Medi- 
care-allowed charges 44' 45 were applied to retrospec- 
tively collected lung cancer follow-up data. Only 
surgical clinic visits and relevant diagnostic tests 
during the disease-free p riod were included in the 
cost analysis. For an average of 3 years of follow-up, 
Medicare-allowed charges totaled $477 for patients 
followed up nonintensively and $2762 for patients 
followed up intensively. Medicare-allowed charges 
were converted to a proxy for actual charges by a 
conversion ratio of 1.62, which the authors calcu- 
lated from actual submitted charge data for 
1992,44, 5 and this resulted in charges of $773 for 
patients followed up nonintensively and $4475 for 
patients followed up intensively. 
A shortcoming in most analyses of follow-up of 
patients with lung cancer is the lack of cost or charge 
data. In response, the current study computes na- 
tionwide average charges associated with the fol- 
low-up of patients with lung cancer after treatment 
for eight separate follow-up strategies identified 
from the literature. 
Methods 
Follow-up strategies. A Medline search of the litera- 
ture for 1980 to 1995 was done to identify citations that 
delineated specific surveillance strategies for patients un- 
dergoing curative resection because of primary lung can- 
cer. Ten articles that depicted eight specific follow-up 
strategies for patients with lung cancer were identified 
(Table I). 
Two reports outlined strategies for follow-up espoused 
by either medical societies or specific ancer centers. One 
was a handbook sponsored by the Connecticut State 
Medical Society in conjunction with other agencies, 3s and 
the second represented the MD Anderson Cancer 
Center approach. 4°Unfortunately, neither eport pre- 
sented specific outcome data such as time to detection 
of recurrence, curative second resections done, survival, 
or quality of life. 
One study reported the mean follow-up strategy that 
resulted from a nationwide survey of all members of the 
Society of Thoracic Surgeons regarding current practice. 2° 
This report documented wide variation among Society 
members regarding the frequency of and rationale for 
surveillance after operation. Though outcome data could 
not reliably be collected, physician motivation was ad- 
dressed. Fewer than half of the respondents believed that 
surveillance resulted in survival benefit for patients with 
either TNM stage I or advanced-stage disease. The study 
detected other potential benefits uch as increased rap- 
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Total visits, tests, charges 
MRI of head Bronchoscopy Sputum cytology CEA Urinalysis Abdomen CT Medicare charges Actual charges* 
0 0 12 0 12 0 $2252 $3648 
0 0 4 3 0 0 $1777 $2878 
0 0 0 0 0 0 $2681 $4343 
0 0 0 0 0 0 $2208 $3576 
0 0 14 0 0 0 $2403 $3892 
0 0 0 0 0 0 $3695 $5986 
0 0 0 0 0 0 $2412 $3908 
0 1 2 0 0 1 $5645 $9145 
0 0 0 0 0 0 $1234 $2000 
0 0 0 0 0 0 $ 946 $1533 
0 0 1 0 0 0 $2583 $4185 
port with primary care physicians and patients and avoid- 
ance of medicolegal conflicts. 
One postoperative follow-up strategy was derived from 
two of the three thoracic surgery textbook refer- 
ences 36'37'42 (Shields 36 did not recommend a specific 
follow-up strategy). Ginsberg, Goldberg, and Waters 42 
37 and Martini and Ginsberg recommended ssentially the 
same strategy, which is based on the yearly rate of recurrence 
after operation. They suggested that systematic, lifelong 
follow-up is crucial in the treatment of patients with lung 
cancer because only 30% to 40% will survive 5 years after 
operation without the development of recurrence and in 
some of these patients treatable second primary tumors 
will develop. Whether such strategies will affect long-term 
survival in the postresection at-risk population cannot be 
determined, because no outcome data were provided. 
One strategy was extracted from a textbook devoted 
exclusively to the follow-up of the patient with cancer. 41 
One additional textbook on follow-up of the patient with 
cancer is currently in preparation, but was not available at 
the time of this review. 46 Beattie 41 suggests that potential 
improvement in quality of life is a major reason for careful 
postoperative surveillance. Insufficient detail was pro- 
vided to determine the data source that served as a basis 
for the suggested strategy of this author. Because the 
published article delineated a 2-year follow-up regimen 
only, the author was contacted to determine his strategy 
for years 3 through 5 after operation (Beattie, personal 
conversation, 1995). His strategy has changed somewhat 
since the time of the original article, For patients without 
symptoms, he currently recommends office visits and chest 
roentgenograms every 2 months in year 1, every 3 months 
in years 2 through 3, every 6 months in year 4, and 
annually thereafter. He no longer recommends sputum 
cytologic tests, carcinoembryonic antigen tests, or liver 
function tests as originally recommended. For patients 
with advanced-stage disease, baseline brain and bone 
scans are also, now recommended. 
One strategy was derived from two articles that re- 
ported on different aspects of the same prospective study. 
The first article from this prospective study compared 
results in 350 patients enrolled in a regular follow-up 
program with results in 145 patients followed up less 
frequently. 43 A major finding of this study was that 
survival did not differ significantly between the two 
groups, athough patients enrolled in a regular follow-up 
program did have higher survival probabilities at all 
intervals. The article did not report he average follow-up 
strategy among patients not in regular follow-up nor did it 
report time to detection of or the frequency of recur- 
rences and second primary tumors. In addition, quality- 
of-life data were not collected. 
Subsequent to that article, 43 four of the original 350 
patients were reported to have primary nonpulmonary 
neoplasms. The second article reported on only the re- 
maining 346 patients with TNMstage I disease nrolled in 
a regular follow-up program. 5 Overall survival was 69% at 
5 years and 62% at 9 years. During the first 5 years of 
follow-up, rates of local recurrence, second primary tu- 
mors, and distant metastases averaged 1.86, 2.5, and 5.0 
per 100 patient-years, respectively. Again, whether the 
same percentage of recurrent cancer cases would have 
been detected with less frequent follow-up cannot be 
determined and quality-of-life data were not collected. 
From neither of these articles can a determination be 
made of whether intensive follow-up detects recurrences 
and second primary tumors earlier, promotes earlier 
treatment of detected recurrences and second primary 
tumors, lengthens urvival, or improves quality of life. 
Two strategies represented the results of retrospective 
analyses of follow-up of patients with lung cancer at single 
facilities where no set follow-up protocol was prespecified. 
The first study retrospectively analyzed follow-up and 
outcomes among 358 patients undergoing lung resection 
at a large cancer center between 1987 and 1991. 8 This 
article makes an important contribution to the literature, 
beyond the cost analysis mentioned earlier. Walsh and 
associates 8 discovered that only 9% (32 patients) of all 
patients followed up had recurrence diagnosed while they 
were still free of symptoms, of which only one third (10 
patients) could be treated with curative intent. In other 
words, in only 3% of all patients did follow-up potentially 
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make a difference in whether curative treatment was 
selected. As a result, the authors suggested a follow-up 
strategy that is less intensive than any other published 
strategy and concluded that follow-up for patients without 
symptoms i unlikely to be cost effective. The limitations 
of that study are the lack of quality-of-life data and the 
biases inherent in all retrospective r search. 
The second retrospective study analyzed follow-up and 
outcomes among 182 patients at a large midwestern VA 
hospital for the period 1982 to 1993. 39 The authors found 
no significant difference in survival between patients fol- 
lowed up intensively and those followed up noninten- 
sively, athough absolute survival differences between 
groups suggested that some benefit of intensive follow-up 
might exist. No patients were curatively treated for recur- 
rence as a result of follow-up. Mean follow-up data for 
both the intensive and nonintensive strategies are pre- 
sented here inasmuch as both represent actual practice 
patterns, athough the results suggested that nonintensive 
follow-up should be recommended. The limitations of the 
study of Walsh and associates 8 apply to this study as well, 
in addition to sample size limitations. Both retrospective 
studies concluded that randomized prospective clinical 
trials are needed to definitively measure whether intensity 
of follow-up makes a difference. 
Cost analyses. Nationwide average charges for 1992 
associated with each of the eight follow-up strategies were 
computed and compared for a single patient with lung 
cancer followed up for 5 years. Charge data were obtained 
from the 1992 Part B Medicare Annual Data file 44 and the 
first-quarter 1992 Hospital Outpatient Bill r i l ey  Average 
allowed charges nationwide for physician services were 
extracted from the Part B Medicare Annual Data file, 
which contains Medicare Part B data by current proce- 
dural terminology code and place of service, such as 
inpatient hospital, outpatient hospital, and office. With 
assistance from the Office of Research and Development 
of the Health Care Financing Administration, corre- 
sponding nationwide average facility charges were ex- 
tracted from the Hospital Outpatient Bill file. 
Physician charges and, where applicable, facility 
charges were summed to obtain a nationwide average 
charge per test or visit. A best-case scenario was assumed 
in calculating charges. For example, it was assumed 
patients were healthy and that additional workup on the 
basis of either symptoms or positive test results was not 
required. Further, it was assumed that each patient sur- 
vived for 5 years, because the purpose of the analysis was 
to measure the cost of the initial 5 years of follow-up. It is 
true that many patients with lung cancer do not live for 5 
years after treatment, but this assumption can be easily 
relaxed. The result would be a table of follow-up costs for 
every combination of TNM stage and projected years of 
survival. Indirect costs, such as time lost from work, 
transportation charges, and child or adult care charges, 
were not factored into this analysis. Similarly, treatment 
costs for new primary lung cancers, recurrences of the 
initial primary lung cancer, and other conditions detected 
during surveillance were ignored, although they may 
impose massive additional expenses for individual pa- 
tients. Under these assumptions, the resulting cost esti- 
mates should be considered conservative and constitute 
baseline estimates of follow-up costs. All costs assumed 
away in this analysis would be considered add-ons to the 
estimates presented. Medicare-allowed charges were held 
constant at the 1992 level as charges were totaled over the 
5-year period for each of the eight strategies and com- 
pared across strategies. Total charges were converted to 
an actual charge proxy by a conversion ratio of 1.62, which 
was calculated from actual submitted charges for 
1992.44, 45 Variation in charges across the eight separate 
follow-up strategies was then reanalyzed. 
Follow-up charges were then calculated for each annual 
United States cohort of patients diagnosed with lung 
cancer. Rough estimates of charges per detected recur- 
rence or second primary tumor were also calculated. It 
was conservatively assumed that 30% to 40% of all 
curatively treated patients with lung cancer would have a 
recurrence during the 5-year period after treatment and 
that annually 3% of all patients would develop a second 
primary cancer. For ease of calculation, no overlap was 
assumed between patients with recurrence and patients in 
whom a second primary tumor developed. Survival by year 
after treatment was estimated as follows: 39.0% at year 1, 
22.3% at year 2, 17.3% at year 3, 14.6% at year 4, and 
12.8% at year 5. 47 
Results 
The strategy with the greatest frequency of any 
single test was that of Fischer 38 with 22 office visits 
and 22 chest roentgenograms during 5 years of 
follow-up. The most intensive 5-year strategy across 
the greatest number of tests was that of Pairolero 5
and Williams 43 and their colleagues with 12 office 
visits, 12 blood tests, 12 chest roentgenograms, 12 
sputum cytologic tests, and 12 urinalyses. Discount- 
ing the original Beattie 41 strategy, which repre- 
sented only 2 years of follow-up, the least intensive 
strategy was that of Walsh and colleagues, 8 with six 
office visits and six chest roentgenograms. 
The range of charges for follow-up of patients 
with lung cancer across strategies was wide. Medi- 
care-allowed charges for 5 years of follow-up varied 
from a low of $946 per patient on the basis of a 
strategy consisting of office visits and chest roent- 
genography to a high of $5645 per patient on the 
basis of an intensive strategy consisting chiefly of 
office visits, CBCs, chest roentgenograms, bone 
scans, sputum cytologic tests, and CTs of the abdo- 
men. When Medicare-allowed charges were con- 
verted to actual charges by a conversion ratio of 
1.62, the range was $1533 to $9145 per patient, a 
fivefold difference. This difference was not sup- 
ported by any data demonstrating reater efficacy 
for the high-cost strategy. 
Not surprisingly, those strategies that used fre- 
quent CT and bronchoscopy during the 5-year pe- 
riod were at the high end of the cost distribution. 
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Those regimens that consisted mainly of some com- 
bination of office visits, chest roentgenograms, blood 
tests, and sputum cytologic tests were the least 
expensive. The lowest cost approaches consist of 
only one or two types of tests. Chest roentgenogra- 
phy and office visits were key components of all the 
strategies analyzed. 
The charge figures quoted here can be considered 
conservative in today's economy inasmuch as they 
were derived from 1992 data. Updating these figures 
to 1995 levels can easily be accomplished bythe use 
of the medical care component of the Consumer 
Price Index. Since 1960, this component has never 
been negativ,e. 4sThe medical care component in- 
creased 5.94% in 1993 and 4.76% in 1994. A 10-year 
(1984 to 1994) average increase in the medical care 
component of 7.02% was used as an estimated 
increase for 1995. The result was a conservative 
estimate of the range of actual charges for 1995 
across the follow-up strategies reviewed here of 
approximately $1820 to $10,861 per patient. This 
yields a difference of $9041 per patient between the 
most intensive and least intensive follow-up strate- 
gies, compared with the original $4699 (an increase 
of $4342 or 4-8% per patient over 3 years). 
Returning to the 1992 unadjusted data, for each 
annual cohort of patients curatively treated for lung 
cancer, the total 5-year follow-up charges (using the 
actual charge proxy) ranged from $7.8 million to 
$164.9 million depending on the intensity of follow- 
up. Averaged[ over the 11,219 to 14,599 recurrences 
or second primary tumors detected during the 
5-year follow-up period for each annual cohort, the 
estimated charge per detected recurrence or second 
primary tumor anged from $534 to $695 for nonin- 
tensive follow-up and from $11,295 to $14,698 for 
intensive follow-up. 
Discussion 
Few attempts have been made to measure the 
relevant costs associated with many medical prac- 
tices, and the follow-up of patients with lung cancer 
is no exception. As this analysis has indicated, 
charges for follow-up can vary by as much as five- 
fold. Though the range of charges for follow-up of 
patients with lung cancer is not as wide as in the case 
of follow-up of patients with colon cancer, 1 variation 
of even this magnitude cannot easily be justified in 
this era of cost containment and health care reform. 
The problem is an especially interesting one because 
little is known about how outcomes vary when the 
follow-up strategy is altered, and the optimal fop 
low-up testing interval has never been defined by 
well-designed trials. No one strategy has been estab- 
lished as more efficacious than any other in terms of 
survival and quality of life, yet the surveillance of 
patients with lung cancer has achieved a greater 
degree of consensus than that for patients with 
colorectal cancer. 
The most persuasive form of evidence would 
come from multisite prospective randomized con- 
trolled trials that tested the benefits of the various 
regimens advocated. Such trials have been reported 
for postoperative surveillance for breast cancer. 49' 5o 
Cost analyses of postoperative lung cancer surveil- 
lance are also lacking. Ideally, such analyses would 
incorporate not only the direct costs of follow-up, 
but also the indirect costs such as time lost from 
work, transportation costs, and child and adult care 
costs. Quality-of-life data should also be examined 
because such data are practically nonexistent in this 
field. 51 Although recent nondefinitive r trospective 
data suggest that choice of treatment may be unaf- 
fected by follow-up, 8'39 quality of life may be either 
directly or indirectly affected by the intensity of the 
follow-up regimen. 
After a review of the literature regarding fol- 
low-up management practices for patients with a 
diagnosis of lung cancer, there are obvious questions 
that arise. Until prospective trials can be conducted, 
how should physicians choose among the recom- 
mended follow-up strategies in the literature in the 
absence of benefit data? Is there one follow-up 
strategy that should be applied to the majority of 
patients until further esearch can be conducted? In
general, we recommend a minimalist strategy, such 
as that of Walsh and colleagues, 8 which consists of 
an office visit and chest roentgenography every 6 
months in year 1 and annually thereafter. This 
strategy is recommended because more intensive 
diagnostic testing has yet to demonstrate survival 
and quality-of-life benefits, although the cases of 
select patients might merit more intensive follow- 
up. At each visit, patients should be questioned 
about he presence of new symptoms or signs indic- 
ative of recurrence such as weight loss, difficulty 
breathing, bony pain, and headaches. The ordering 
of further tests would be based on this clinical 
evidence. 
One limitation of the current analysis is that 
actual patients with lung cancer were not followed 
up prospectively to estimate costs. Though several 
strategies included in the analysis are based on 
actual patient data, a large prospective study would 
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allow one to collect data on the costs of many factors 
assumed away in this analysis, such as diagnosis and 
treatment costs for patients with symptoms or pos- 
itive test results. 
A second limitation is that this study examines 
only follow-up after resection. Four times the num- 
ber of curatively treated patients, or 140,000 pa- 
tients, are treated nonoperatively each year. Such 
patients undergoing chemotherapy or radiation 
therapy are often followed up intensively after ther- 
apy. The cost ramifications of current follow-up 
practice for this large patient population may be 
even greater than for curatively treated patients with 
much less potential for improving survival. 
Even the moderate cost differentials among sur- 
veillance strategies identified in this study will be 
increasingly difficult to sustain in the current com- 
petitive medical practice environment in which cost 
containment is such a dominant force. Though the 
variation in costs is moderate, the number of pa- 
tients with lung Cancer is large and, therefore, the 
total costs are staggering. Future research in the 
form of clinical trials is clearly needed to compare 
intensities of follow-up and to determine whether 
higher costs are substantiated by improved quality of 
life and longer survival. 
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